PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11893254-8 2002 It has also been observed that both the brain and liver became much more sensitive to the CP-induced teratogenic insult if the embryos were exposed to a combined treatment with the teratogen and sodium salicylate that suppressed NF-kappaB DNA-binding activity in these organs. Sodium Salicylate 195-212 nuclear factor kappa B subunit 1 Homo sapiens 229-238 15598438-5 2005 We show here that inhibition of NF-kappaB with the non-specific NF-kappaB inhibitors SSC (sodium salicylate), DCIC (3,4-dichloroisocoumarin) and PAO (phenylarsine oxide) results in a downregulation of TNF-alpha-induced CCL27 production. Sodium Salicylate 90-107 nuclear factor kappa B subunit 1 Homo sapiens 32-41 15598438-5 2005 We show here that inhibition of NF-kappaB with the non-specific NF-kappaB inhibitors SSC (sodium salicylate), DCIC (3,4-dichloroisocoumarin) and PAO (phenylarsine oxide) results in a downregulation of TNF-alpha-induced CCL27 production. Sodium Salicylate 90-107 nuclear factor kappa B subunit 1 Homo sapiens 64-73 15472206-8 2004 Pioglitazone and sodium salicylate thus protect human islets against the detrimental effects of IL-1beta and high glucose by blocking NFkappaB activation and may therefore be useful in retarding the manifestation and progression of diabetes. Sodium Salicylate 17-34 nuclear factor kappa B subunit 1 Homo sapiens 134-142 12752124-7 2003 The involvement of NF-kappaB was assessed using sodium salicylate, which inhibits NF-kappaB activation. Sodium Salicylate 48-65 nuclear factor kappa B subunit 1 Homo sapiens 19-28 12752124-7 2003 The involvement of NF-kappaB was assessed using sodium salicylate, which inhibits NF-kappaB activation. Sodium Salicylate 48-65 nuclear factor kappa B subunit 1 Homo sapiens 82-91 15893602-11 2005 An anti-inflammatory and anti-NF-(kappa)B drug, sodium salicylate, significantly blocked A(beta)-induced APOE promoter function. Sodium Salicylate 48-65 nuclear factor kappa B subunit 1 Homo sapiens 30-41 15472206-2 2004 The aim of this study was to determine whether two drugs believed to block NFkappaB activation, the thiazolidinedione (glitazone) pioglitazone and the nonsteroidal antiinflammatory drug sodium salicylate, can protect human beta-cells against the toxic effects of IL-1beta and high glucose in vitro. Sodium Salicylate 186-203 nuclear factor kappa B subunit 1 Homo sapiens 75-83 10428782-3 1999 Sodium salicylate (NaSal) can block NF-kappaB activation by inhibiting IkappaBalpha phosphorylation. Sodium Salicylate 0-17 nuclear factor kappa B subunit 1 Homo sapiens 36-45 12094615-7 2001 These effects were preventable by cotreatment with inhibitors of NF-kappa B activity, such as sodium salicylate, aspirin, or pyrrolidine dithiocarbamate. Sodium Salicylate 94-111 nuclear factor kappa B subunit 1 Homo sapiens 65-75 10652242-6 2000 Interestingly, the apigenin-mediated VDR suppression was counteracted by the NFkappaB inhibitors sodium salicylate and caffeic acid phenethyl ester. Sodium Salicylate 97-114 nuclear factor kappa B subunit 1 Homo sapiens 77-85 10480951-4 1999 Recently, we demonstrated that both aspirin and sodium salicylate, but not indomethacin, inhibited the activity of an IkappaB kinase beta (IKKbeta) that is required to activate the nuclear factor-kappaB (NF-kappaB) pathway. Sodium Salicylate 48-65 nuclear factor kappa B subunit 1 Homo sapiens 181-202 10480951-4 1999 Recently, we demonstrated that both aspirin and sodium salicylate, but not indomethacin, inhibited the activity of an IkappaB kinase beta (IKKbeta) that is required to activate the nuclear factor-kappaB (NF-kappaB) pathway. Sodium Salicylate 48-65 nuclear factor kappa B subunit 1 Homo sapiens 204-213 11841687-4 2002 Inhibition of NF-kappaB by pyrolidine dithiocarbamate and sodium salicylate, and serine-threonine and tyrosine kinase by starosporine as well as phosphatidylinositide-3-kinase (PI-3-K) by wortmannin could prevent the effects of HA and CSA on the expression of HLA-DR, CD40, CD80 and CD86 in various degrees. Sodium Salicylate 58-75 nuclear factor kappa B subunit 1 Homo sapiens 14-23 10553090-1 1999 Sodium salicylate (NaSal) and other nonsteroidal anti-inflammatory drugs (NSAIDs) coordinately inhibit the activity of NF-kappa B, activate heat shock transcription factor 1 and suppress cytokine gene expression in activated monocytes and macrophages. Sodium Salicylate 0-17 nuclear factor kappa B subunit 1 Homo sapiens 119-129 10428782-3 1999 Sodium salicylate (NaSal) can block NF-kappaB activation by inhibiting IkappaBalpha phosphorylation. Sodium Salicylate 19-24 nuclear factor kappa B subunit 1 Homo sapiens 36-45 10199558-6 1999 To investigate the potential role of NFkappaB in this TNFalpha effect, we treated cells with sodium salicylate (NaS), an inhibitor of NFkappaB translocation. Sodium Salicylate 93-110 nuclear factor kappa B subunit 1 Homo sapiens 134-142 10402163-7 1999 Aspirin and sodium salicylate inhibit activation of NF-KB by blocking IkappaB kinase, a key enzyme in NF-kappaB activation. Sodium Salicylate 12-29 nuclear factor kappa B subunit 1 Homo sapiens 102-111 8972019-0 1996 Acetylsalicylic acid and sodium salicylate inhibit LPS-induced NF-kappa B/c-Rel nuclear translocation, and synthesis of tissue factor (TF) and tumor necrosis factor alfa (TNF-alpha) in human monocytes. Sodium Salicylate 25-42 nuclear factor kappa B subunit 1 Homo sapiens 63-73 10210643-2 1999 Sodium salicylate (NaSal) inhibits NF-kappaB activation by limiting phosphorylation and degradation of its bound inhibitor protein, IkappaB-alpha. Sodium Salicylate 0-17 nuclear factor kappa B subunit 1 Homo sapiens 35-44 10210643-2 1999 Sodium salicylate (NaSal) inhibits NF-kappaB activation by limiting phosphorylation and degradation of its bound inhibitor protein, IkappaB-alpha. Sodium Salicylate 19-24 nuclear factor kappa B subunit 1 Homo sapiens 35-44 9187256-10 1997 Thus, sodium salicylate is an effective inhibitor of COX-2 activity at concentrations far below those required to inhibit NF-kappaB (20 mg/ml) activation and is easily displaced by arachidonic acid. Sodium Salicylate 6-23 nuclear factor kappa B subunit 1 Homo sapiens 122-131 9722548-6 1998 Activation of NF-kappaB and degradation of IkappaB-alpha were prevented by the NF-kappaB inhibitors sodium salicylate and MG-132. Sodium Salicylate 100-117 nuclear factor kappa B subunit 1 Homo sapiens 14-23 9722548-6 1998 Activation of NF-kappaB and degradation of IkappaB-alpha were prevented by the NF-kappaB inhibitors sodium salicylate and MG-132. Sodium Salicylate 100-117 nuclear factor kappa B subunit 1 Homo sapiens 79-88 9722548-9 1998 Induction of COX-2 and stimulation of COX activity by ET-1 and TNF-alpha were prevented by sodium salicylate and MG-132, suggesting that activation of NF-kappaB by either factor is needed for stimulation of COX-2. Sodium Salicylate 91-108 nuclear factor kappa B subunit 1 Homo sapiens 151-160 9686761-7 1998 Furthermore, by reducing ROS, aspirin and sodium salicylate inhibit CMV-induced NFkappaB activation, the ability of IE72 to transactivate its promoter, CMV IE gene expression after infection of SMCs, and CMV replication in SMCs. Sodium Salicylate 42-59 nuclear factor kappa B subunit 1 Homo sapiens 80-88 9191851-9 1997 Sodium salicylate and aspirin, inhibitors of NF-kappa B activation, abolished transcriptional induction of all these cytokines by RSV. Sodium Salicylate 0-17 nuclear factor kappa B subunit 1 Homo sapiens 45-55 9467376-0 1996 Inhibition of nuclear factor kappa B subunit p65 mRNA accumulation in lipopolysaccharide-stimulated human monocytic cells treated with sodium salicylate. Sodium Salicylate 135-152 nuclear factor kappa B subunit 1 Homo sapiens 14-36 9467376-8 1996 High doses of sodium salicylate suppressed NF-kappa B p65 mRNA accumulation, resulting in suppression of total NF-kappa B, p50 on tissue oligonucleotide had no effects on lipopolysaccharide-induced NF-kappa B activation. Sodium Salicylate 14-31 nuclear factor kappa B subunit 1 Homo sapiens 43-53 9467376-8 1996 High doses of sodium salicylate suppressed NF-kappa B p65 mRNA accumulation, resulting in suppression of total NF-kappa B, p50 on tissue oligonucleotide had no effects on lipopolysaccharide-induced NF-kappa B activation. Sodium Salicylate 14-31 nuclear factor kappa B subunit 1 Homo sapiens 111-121 9467376-8 1996 High doses of sodium salicylate suppressed NF-kappa B p65 mRNA accumulation, resulting in suppression of total NF-kappa B, p50 on tissue oligonucleotide had no effects on lipopolysaccharide-induced NF-kappa B activation. Sodium Salicylate 14-31 nuclear factor kappa B subunit 1 Homo sapiens 123-126 9467376-8 1996 High doses of sodium salicylate suppressed NF-kappa B p65 mRNA accumulation, resulting in suppression of total NF-kappa B, p50 on tissue oligonucleotide had no effects on lipopolysaccharide-induced NF-kappa B activation. Sodium Salicylate 14-31 nuclear factor kappa B subunit 1 Homo sapiens 111-121 8621937-3 1996 Recent work has suggested that some nonsteroidal anti-inflammatory agents, including sodium salicylate and aspirin, can inhibit NF-kappa B-dependent gene activation. Sodium Salicylate 85-102 nuclear factor kappa B subunit 1 Homo sapiens 128-138 8676466-7 1996 The functional response to Tat is impaired upon cell treatment with a kappaB site decoy or with sodium salicylate, an inhibitor of NF-kappaB activation. Sodium Salicylate 96-113 nuclear factor kappa B subunit 1 Homo sapiens 131-140 8621937-5 1996 We found that sodium salicylate inhibited activation of NF-kappa B (p50/p65 and p65/p65) by preventing phosphorylation and subsequent degradation of the inhibitor 1 kappa B-alpha. Sodium Salicylate 14-31 nuclear factor kappa B subunit 1 Homo sapiens 56-66 8621937-5 1996 We found that sodium salicylate inhibited activation of NF-kappa B (p50/p65 and p65/p65) by preventing phosphorylation and subsequent degradation of the inhibitor 1 kappa B-alpha. Sodium Salicylate 14-31 nuclear factor kappa B subunit 1 Homo sapiens 68-71 27852976-6 2016 Moreover, systemic administration of sodium salicylate, an FDA-approved NF-kappaB inhibitor, decreased inflammatory gene expression and improved repair in aged muscle. Sodium Salicylate 37-54 nuclear factor kappa B subunit 1 Homo sapiens 72-81 8533099-0 1995 The effect of sodium salicylate and aspirin on NF-kappa B. Sodium Salicylate 14-31 nuclear factor kappa B subunit 1 Homo sapiens 47-57 26643666-4 2016 5-aminosalicylic acid (5-ASA) and sodium salicylate are known to suppress NFkappaB activation by inhibiting inhibitor of kappa B kinase (IKkappaB). Sodium Salicylate 34-51 nuclear factor kappa B subunit 1 Homo sapiens 74-82 17646662-7 2007 Sodium salicylate achieved its effects by reducing the elevated NF-kappaB responsiveness and FLIP levels and restoring the apoptotic response of TNF rather than the proliferative/proinflammatory effects of the cytokine in these cancer cells. Sodium Salicylate 0-17 nuclear factor kappa B subunit 1 Homo sapiens 64-73 20959117-6 2011 In addition, the observed effects were independent of the ability of sodium salicylate to inhibit cyclooxygenase-2 or NFkappaB. Sodium Salicylate 69-86 nuclear factor kappa B subunit 1 Homo sapiens 118-126 16141522-4 2005 Using sodium salicylate, a known NF-kappaB inhibitor, further confirmed this conclusion. Sodium Salicylate 6-23 nuclear factor kappa B subunit 1 Homo sapiens 33-42 16373365-6 2006 Results from reverse transcription-PCR and flow cytometry analysis of HUTEC indicate that the interaction with Daudi cells induce an increased expression of IL-6 and IL-8 mRNA and cell-surface expression of intercellular adhesion molecule-1, all of which were prevented by sodium salicylate, an inhibitor of NF-kappaB activation. Sodium Salicylate 273-290 nuclear factor kappa B subunit 1 Homo sapiens 308-317 16432451-0 2006 Sodium salicylate inhibits TNF-alpha-induced NF-kappaB activation, cell migration, invasion and ICAM-1 expression in human melanoma cells. Sodium Salicylate 0-17 nuclear factor kappa B subunit 1 Homo sapiens 45-54 16432451-2 2006 The aim of this study was to investigate the effect of the non-steroidal anti-inflammatory agent sodium salicylate on TNF-alpha-induced activation of the transcription factor nuclear factor-kappaB (NF-kappaB) and upregulation of intercellular adhesion molecule-1 (ICAM-1), and TNF-alpha-stimulated cell migration and invasion through fibronectin. Sodium Salicylate 97-114 nuclear factor kappa B subunit 1 Homo sapiens 175-196 16432451-2 2006 The aim of this study was to investigate the effect of the non-steroidal anti-inflammatory agent sodium salicylate on TNF-alpha-induced activation of the transcription factor nuclear factor-kappaB (NF-kappaB) and upregulation of intercellular adhesion molecule-1 (ICAM-1), and TNF-alpha-stimulated cell migration and invasion through fibronectin. Sodium Salicylate 97-114 nuclear factor kappa B subunit 1 Homo sapiens 198-207 16432451-3 2006 HBL human melanoma cells were pre-incubated with sodium salicylate prior to stimulation with TNF-alpha for 24 h. NF-kappaB activation was measured using an assay that detects changes in the expression of a luciferase reporter gene under the direct control of NF-kappaB transcriptional activity. Sodium Salicylate 49-66 nuclear factor kappa B subunit 1 Homo sapiens 113-122 16432451-5 2006 Sodium salicylate inhibited TNF-alpha-stimulated NF-kappaB activation in melanoma cells in a concentration-dependent manner, and this was achieved with pre-incubation times as short as 15 min. Sodium Salicylate 0-17 nuclear factor kappa B subunit 1 Homo sapiens 49-58 16432451-8 2006 In conclusion, sodium salicylate effectively inhibited TNF-alpha-induced upregulation of NF-kappaB, ICAM-1 expression, in-vitro migration and invasion in human melanoma cells, indicating that non-steroidal anti-inflammatory drugs may be a useful therapeutic approach to oppose inflammation-induced melanoma invasion and metastasis in vivo. Sodium Salicylate 15-32 nuclear factor kappa B subunit 1 Homo sapiens 89-98 16402387-7 2006 Treatment of PC-3 high invasive and RhoA Q63E cells with sodium salicylate or lactacystin inhibited NF-kappaB and invasion, while pyrrolidine dithiocarbamate (PDTC) treatment of PC-3 high invasive cells inhibited NF-kappaB only. Sodium Salicylate 57-74 nuclear factor kappa B subunit 1 Homo sapiens 100-109 16402387-7 2006 Treatment of PC-3 high invasive and RhoA Q63E cells with sodium salicylate or lactacystin inhibited NF-kappaB and invasion, while pyrrolidine dithiocarbamate (PDTC) treatment of PC-3 high invasive cells inhibited NF-kappaB only. Sodium Salicylate 57-74 nuclear factor kappa B subunit 1 Homo sapiens 213-222